Pancreatic Cancer Research

ResearcherPennsylvania State UniversityActive in the last 2 years

Xiuchao Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3205-8544; OpenAlex author ID A5050510042, A5130750480. Sources: OpenAlex.

Their work

Papers
63 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
108
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 3 papers · 2016: 3 papers · 2017: 5 papers · 2018: 2 papers · 2019: 4 papers · 2020: 3 papers · 2021: 4 papers · 2022: 5 papers · 2023: 8 papers · 2024: 5 papers · 2025: 6 papers · 2026: 10 papers

Papers 50 of 63

  1. Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenance. Last author DOI 10.1002/advs.202507346↗
  2. Leucine Aminopeptidase-Responsive Bioluminescent Probe for Point-of-Care Diagnosis of Pancreatic Cancer in Blood and Urine. Co-author DOI 10.1021/acs.analchem.6c03034↗
  3. Cancer cell-specific FOXP3 licenses MMP19-dependent matrix remodeling and metastatic dissemination in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-026-04025-y↗
  4. Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-025-02561-9↗
  5. Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. Co-author DOI 10.1038/s41392-026-02641-4↗
  6. Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 tri… Co-author DOI 10.1038/s41392-026-02966-0↗
  7. NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. Co-author DOI 10.1038/s41467-026-68409-0↗
  8. Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilita… Co-author DOI 10.1136/gutjnl-2025-335790↗
  9. Development and Prospective Validation of a Cell-free DNA-Based Model for the Early Detection of Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-25-0323↗
  10. Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring. Co-author DOI 10.1158/2159-8290.cd-25-1627↗
  11. The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.217408↗
  12. A CD147-targeted small-molecule inhibitor potentiates gemcitabine efficacy by triggering ferroptosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.xcrm.2025.102292↗
  13. Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells. Co-author DOI 10.1038/s41422-025-01098-4↗
  14. Adaptation to cystine limitation stress confers a targetable lipid metabolism vulnerability in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-025-68099-0↗
  15. CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. Last author DOI 10.20892/j.issn.2095-3941.2025.0058↗
  16. Integrated pretreatment stratification system for pancreatic cancer: combining anatomical resectability and tumor biological parameters. Co-author DOI 10.20892/j.issn.2095-3941.2025.0213↗
  17. Survival outcomes of adjuvant chemotherapy in patients with stage I pancreatic cancer stratified by pathologic risk. Co-author DOI 10.1016/j.surg.2024.07.047↗
  18. Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41388-024-02938-0↗
  19. Correction: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01721-z↗
  20. BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Co-author DOI 10.1126/sciadv.adj8650↗
  21. CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-l… Co-author DOI 10.1136/gutjnl-2024-332371↗
  22. Crosstalk Between Peripheral Innervation and Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12264-023-01082-1↗
  23. Retraction notice to "HIF-1α mediates tumor-nerve interactions through the up-regulation of GM-CSF in pancreatic ductal adenocarcinoma" [Cancer Lett. 453 (2019… Co-author DOI 10.1016/j.canlet.2023.216059↗
  24. BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01478-5↗
  25. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective… Co-author DOI 10.1097/js9.0000000000000425↗
  26. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. Co-author DOI 10.1186/s13046-023-02671-8↗
  27. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endopl… Co-author DOI 10.1186/s13046-023-02814-x↗
  28. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2023.0039↗
  29. Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study. Co-author DOI 10.3389/fonc.2023.1276037↗
  30. Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215864↗
  31. ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour-stromal IL-1β/NF-κB/ESE3 signalling axis. Co-author DOI 10.1038/s41416-022-01927-y↗
  32. BZW1 Facilitates Glycolysis and Promotes Tumor Growth in Pancreatic Ductal Adenocarcinoma Through Potentiating eIF2α Phosphorylation. Co-author DOI 10.1053/j.gastro.2021.12.249↗
  33. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4. Co-author DOI 10.1136/gutjnl-2020-321952↗
  34. Mitochondrial Calcium Uniporter Drives Metastasis and Confers a Targetable Cystine Dependency in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-21-3230↗
  35. Serum insulin-like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma-associated malnutrition and muscle wasting. Co-author DOI 10.1002/jcsm.12692↗
  36. PERK-eIF2α-ERK1/2 axis drives mesenchymal-endothelial transition of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.05.021↗
  37. CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms. Co-author DOI 10.1016/j.canlet.2021.07.024↗
  38. Alteration of nanomechanical properties of pancreatic cancer cells through anticancer drug treatment revealed by atomic force microscopy. Co-author DOI 10.3762/bjnano.12.101↗
  39. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effec… Co-author DOI 10.1038/s41392-020-0144-8↗
  40. MicroRNA-608 promotes apoptosis via BRD4 downregulation in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2019.11246↗
  41. IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer. Co-author DOI 10.7150/thno.42416↗
  42. RETRACTED: HIF-1α mediates tumor-nerve interactions through the up-regulation of GM-CSF in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2019.03.036↗
  43. LOX and ACSL5 as potential relapse markers for pancreatic cancer patients. Co-author DOI 10.1080/15384047.2018.1564565↗
  44. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1084/jem.20180749↗
  45. LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen-Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation. Co-author DOI 10.1158/1078-0432.ccr-18-3533↗
  46. Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. First author DOI 10.1016/j.biomaterials.2017.12.015↗
  47. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of … Co-author DOI 10.1053/j.gastro.2017.09.039↗
  48. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. First author DOI 10.1016/j.canlet.2017.05.015↗
  49. Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression. Co-author DOI 10.1038/ncomms14035↗
  50. Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/onc.2016.458↗

Closest collaborators

The 25 strongest of 108 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jihui Hao · 53 shared papers, 2011–2026 · strength 6.46
  2. Tiansuo Zhao · 46 shared papers, 2011–2026 · strength 5.99
  3. Chongbiao Huang · 31 shared papers, 2015–2026 · strength 4.03
  4. Song Gao · 29 shared papers, 2012–2026 · strength 3.68
  5. Shengyu Yang · 26 shared papers, 2016–2026 · strength 3.21
  6. Yongjie Xie · 15 shared papers, 2022–2026 · strength 2.74
  7. Tianxing Zhou · 14 shared papers, 2019–2026 · strength 2.42
  8. Jing Liu · 14 shared papers, 2019–2026 · strength 2.01
  9. Chuntao Gao · 13 shared papers, 2014–2026 · strength 1.77
  10. Jun Yu · 7 shared papers, 2024–2026 · strength 1.39
  11. Chao Xu · 8 shared papers, 2017–2026 · strength 1.37
  12. Zengxun Li · 9 shared papers, 2017–2026 · strength 1.17
  13. Yukuan Feng · 6 shared papers, 2024–2026 · strength 1.16
  14. Huizhi Sun · 7 shared papers, 2021–2026 · strength 1.15
  15. Yiping Zou · 5 shared papers, 2023–2025 · strength 0.93
  16. Liangliang Wu · 7 shared papers, 2019–2025 · strength 0.91
  17. He Ren · 11 shared papers, 2011–2026 · strength 0.87
  18. Shangheng Shi · 4 shared papers, 2026 · strength 0.80
  19. Chao Yang · 4 shared papers, 2025–2026 · strength 0.80
  20. Junjin Wang · 3 shared papers, 2023–2026 · strength 0.77
  21. Yuexiang Liang · 3 shared papers, 2024–2026 · strength 0.61
  22. Song Gao · 3 shared papers, 2025–2026 · strength 0.60
  23. Shaofei Chang · 3 shared papers, 2023–2025 · strength 0.59
  24. Qingxiao Fang · 3 shared papers, 2025–2026 · strength 0.59
  25. Kaiyuan Wang · 3 shared papers, 2023–2025 · strength 0.59

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.